Citius Oncology, Inc. Operating Cash Flow
Citius Oncology, Inc. (CTOR) reported Operating Cash Flow of -$13.90 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- Citius Oncology, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$2.71M.
- Citius Oncology, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$3.83M.
- Citius Oncology, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$7.35M.
- Citius Oncology, Inc. net cash provided by (used in) operating activities for the quarter ending 2024-06-30 was -$366.11K.
- Citius Oncology, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$5.49M, a 4446.59% decline from fiscal 2024.
- Citius Oncology, Inc. net cash provided by (used in) operating activities for fiscal 2024 was $126.35K.
- Citius Oncology, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$601.30K.
- Citius Oncology, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$47.97K.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-14 | -$6.54M derived: sum of 2 quarters · filed 2026-08-14 | -$13.90M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$3.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | -$11.19M 10-Q · filed 2026-05-15 | ||
| 2025-12-31 | -$7.35M 10-Q · filed 2026-02-13 | |||
| 2025-09-30 | -$5.49M 10-K · filed 2025-12-23 | |||
| 2024-09-30 | $126.35K 10-K · filed 2025-12-23 | |||
| 2024-06-30 | -$366.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$557.80K 10-Q · filed 2024-08-09 | -$776.57K derived: sum of 3 quarters · filed 2024-08-09 | -$890.04K derived: sum of 4 quarters · filed 2024-08-09 |
| 2024-03-31 | -$191.69K 10-Q · filed 2024-05-20 | -$410.47K derived: sum of 2 quarters · filed 2024-05-20 | -$523.94K derived: sum of 3 quarters · filed 2024-05-20 | -$624.20K derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-12-31 | -$218.78K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | -$332.25K derived: sum of 2 quarters · filed 2024-04-16 | -$432.50K derived: sum of 3 quarters · filed 2024-08-09 | -$601.30K 10-K · filed 2024-04-16 |
| 2023-09-30 | -$113.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-20 | -$213.73K derived: sum of 2 quarters · filed 2024-08-09 | -$382.53K 10-Q · filed 2023-11-20 | |
| 2023-06-30 | -$100.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$269.06K 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | -$168.80K 10-Q · filed 2024-05-20 | |||
| 2022-12-31 | -$47.97K 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |